➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
McKinsey
Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson

Last Updated: July 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IVACAFTOR

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Ivacaftor

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00457821 ↗ Safety Study of Ivacaftor in Subjects With Cystic Fibrosis Completed Cystic Fibrosis Foundation Therapeutics Phase 2 2007-05-01 The purpose of this study was to evaluate the safety and tolerability of ivacaftor in patients with cystic fibrosis (CF) who were aged 18 years or older and have a G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor is a potent and selective CFTR potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein. Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic AMP-dependent protein kinase A (PKA) activation.
NCT00457821 ↗ Safety Study of Ivacaftor in Subjects With Cystic Fibrosis Completed Vertex Pharmaceuticals Incorporated Phase 2 2007-05-01 The purpose of this study was to evaluate the safety and tolerability of ivacaftor in patients with cystic fibrosis (CF) who were aged 18 years or older and have a G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor is a potent and selective CFTR potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein. Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic AMP-dependent protein kinase A (PKA) activation.
NCT00909532 ↗ Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation Completed Cystic Fibrosis Foundation Therapeutics Phase 3 2009-06-01 The purpose of this study was to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis aged 12 years and older who have the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor is a potent and selective CFTR potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein. Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic AMP-dependent protein kinase A (PKA) activation.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ivacaftor

Condition Name

Condition Name for Ivacaftor
Intervention Trials
Cystic Fibrosis 100
Chronic Obstructive Pulmonary Disease 3
Diabetes 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ivacaftor
Intervention Trials
Cystic Fibrosis 103
Fibrosis 94
Lung Diseases 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ivacaftor

Trials by Country

Trials by Country for Ivacaftor
Location Trials
United States 870
Canada 68
United Kingdom 62
Australia 46
France 43
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ivacaftor
Location Trials
Massachusetts 41
Pennsylvania 36
Alabama 36
Missouri 36
Illinois 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ivacaftor

Clinical Trial Phase

Clinical Trial Phase for Ivacaftor
Clinical Trial Phase Trials
Phase 4 11
Phase 3 51
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ivacaftor
Clinical Trial Phase Trials
Completed 34
Not yet recruiting 31
Recruiting 30
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ivacaftor

Sponsor Name

Sponsor Name for Ivacaftor
Sponsor Trials
Vertex Pharmaceuticals Incorporated 83
Cystic Fibrosis Foundation Therapeutics 13
University of Alabama at Birmingham 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ivacaftor
Sponsor Trials
Industry 90
Other 59
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Mallinckrodt
Baxter
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.